...
首页> 外文期刊>The Lancet >The Women's Health Initiative Memory Study: findings and implications for treatment
【24h】

The Women's Health Initiative Memory Study: findings and implications for treatment

机译:妇女健康倡议记忆研究:发现和对治疗的影响

获取原文
获取原文并翻译 | 示例

摘要

Background The population of the developed world is ageing; consequently there is an increasing prevalence of age-related neuropsychiatric disorders, such as dementia of any cause and Alzheimer's disease (AD), for which few treatments are available. Observational studies suggested that hormone therapy (HT) might protect postmenopausal women against cognitive decline and AD. However, the results of randomised controlled trials in women age 65 years and older were negative. There has been extensive media coverage of these trials and many doctors are asked whether HT improves or worsens brain function in younger women who are prescribed HT for the treatment of menopausal symptoms.Recent developments The Women's Health Inititiative Memory Study (WHIMS) was a multicentre, randomised, double-blind, placebo-controlled clinical trial in which a subgroup of women who participated in the Women's Health Initiative study were assessed for the effects of HT on dementia and mild cognitive impairment. There were two study arms, one involving 4532 postmenopausal women who received continuous combined oestrogen (conjugated equine oestrogens [CEE] plus medroxyprogesterone acetate) or placebo, and the other involving 2947 hysterectomised women randomised to continuous unopposed CEE or placebo. All participants were age 65 years or older. CEE with or without medroxyprogesterone acetate, given to women age 65 years and older, does not protect against dementia or cognitive decline, but substantially increases the risk of dementia of any cause and cognitive decline.Where next? WHIMS answered critically important questions about whether HT can protect against dementia in elderly women who start HT some years after menopause. However, several clinically important questions are unanswered, including questions about the generalisability of WHIMS to groups of women for whom HT is an indication-perimenopausal women and those soon after menopause who have menopausal symptoms-and other methods of treatment delivery and treatment regimens.
机译:背景发达国家的人口正在老龄化。因此,与年龄有关的神经精神疾病(例如,任何原因的痴呆症和阿尔茨海默氏病(AD))的患病率正在上升,但目前尚无治疗方法。观察性研究表明,激素疗法(HT)可以保护绝经后妇女免于认知能力下降和AD。但是,在65岁以上的女性中进行的随机对照试验结果为阴性。这些试验已被广泛的媒体报道,许多医生被问到是否HT可以改善或恶化经更年期症状治疗而开处方HT的年轻妇女的脑功能。一项随机,双盲,安慰剂对照的临床试验,其中评估了一部分参加妇女健康倡议研究的女性亚组的HT对痴呆症和轻度认知障碍的影响。有两个研究小组,一个涉及4532名接受持续联合雌激素(共轭马雌激素[CEE]加醋酸甲羟孕酮)或安慰剂的绝经后妇女,另一名涉及2947例接受连续无对抗CEE或安慰剂子宫切除术的妇女。所有参与者年龄均在65岁以上。 65岁及以上年龄的女性接受或不服用醋酸甲羟孕酮的CEE不能预防痴呆或认知功能减退,但会大大增加任何原因和认知功能减退的痴呆风险。 WHIMS回答了有关HT是否可以预防绝经后几年开始HT的老年妇女痴呆症的至关重要的问题。但是,一些临床上重要的问题尚未得到解答,包括有关WHIMS对HT是围绝经期适应症的妇女群体以及绝经后不久出现绝经症状的妇女群体的普遍性的问题,以及其他治疗方法和治疗方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号